Professor Mok’s main research focus is molecular targeted therapy of lung cancer; he was the principal investigator and first author for the landmark IRESSA Pan-Asia Study (IPASS), which was the first study that confirmed the application of precision medicine for advanced lung cancer. He has also led and co-led multiple international Phase III studies that address various aspects of the management of advanced lung cancer.

Professor Mok trained at the University of Alberta, Canada, and subsequently completed a fellowship in medical oncology at the Princess Margaret Hospital in Toronto. After working as a community oncologist in Toronto, Canada, for 7 years, he returned to Hong Kong in 1996 to pursue an academic career. He has made significant contributions to lung cancer educational activity, including contributions to the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), the Chinese Society of Clinical Oncology (CSCO), and the European Society for Medical Oncology (ESMO). He has received multiple awards, including the Bonnie J. Addario Award in 2015, Fellowship of the American Society of Clinical Oncology in 2017, the ESMO Lifetime Achievement Award in 2018, and the 6th Kobayashi Foundation Award and the Giants of Cancer Care award in 2020.

Professor Mok served as an associate editor for thoracic oncology for the Journal of Clinical Oncology and is currently an associate editor of Clinical Lung Cancer. He is a past president and past treasurer of the International Association for the Study of Lung Cancer. He is on the board of directors of the ACT Genomics–Sanomics Group, AstraZeneca, Aurora Tele-Oncology, and HutchMed (China).